Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14198669 | 0.83 | SCD (0.49) | SCDNPC1RAB9ASMN1; SMN2S1PR3 | |
| SCHEMBL31644750 | 0.77 | SCD (0.52) | SCDNPC1RAB9ASMN1; SMN2S1PR3 | |
| SCHEMBL5379547 | 0.77 | SCD (0.37) | SCDNPC1RAB9ASMN1; SMN2S1PR3 | |
| SCHEMBL345666 | 0.74 | NOTUM (0.43) | NPC1RAB9ASMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL3932995 | 0.74 | NOTUM (0.43) | NPC1RAB9ASMN1; SMN2S1PR3S1PR1 | |
| SCHEMBL4411769 | 0.74 | F2RL1 (0.40) | SCDNPC1RAB9ASMN1; SMN2S1PR3 | |
| SCHEMBL1320408 | 0.74 | VHL (0.41) | SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2619071 | 0.73 | THRB (0.48) | NPC1RAB9ASMN1; SMN2SMYD3 | |
| SCHEMBL5988237 | 0.73 | ALDH1A1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1HDAC6 | |
| Hydrochloric Acid SCHEMBL4010638 | 0.73 | NOTUM (0.42) | NPC1RAB9ASMN1; SMN2S1PR3S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | claimed |
| US-7220865-B2 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-05-22 | — | — | US | claimed |
| EP-1735288-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005095361-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | claimed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-7241786-B2 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7220865-B2 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1735288-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1636220-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005095361-A1 | ISOXAZOLE- AND ISOTHIAZOLE-AMINE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004099200-A1 | ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242666-A1 | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders | NPY1R, PARK7, IAPP | SCD 4791/4885NPC1 351/4885RAB9A 568/4885 |
| US-20050222149-A1 | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders | NPY1R, PSEN1, APP | SCD 4772/4885NPC1 821/4885RAB9A 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.